ANNA M LITVAK

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology LIVINGSTON, NJ NPI 1326319302

General Payments — all program years on this page

$20,666.26

  • Category: General Payments
  • Program years: PY2018–2023
  • Record count: 66
  • As of (CMS publication): 2026-01-23

Latest program year (PY2023): $3,102.23 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2023) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $2,745.002
Food and Beverage $178.389
Long term medical supply or device loan $166.662
Education $12.191

By paying entity

Latest program year (PY2023) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $1,680.342
Stemline Therapeutics Inc. $1,080.001
NOVARTIS PHARMACEUTICALS CORPORATION $219.306
EISAI INC. $45.102
Foundation Medicine, Inc. $39.631
TOLMAR, INC. $21.171
Gilead Sciences, Inc. $16.691

By program year

Program yearAmountRecords
2018 $1,200.428
2019 $1,385.3412
2020 $5,680.6012
2021 $3,087.6911
2022 $6,209.989
2023 $3,102.2314

Records — PY2023 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1000085949 Novartis Pharmaceuticals Corporation $12.19 03/07/2023 Education Undisputed 01/23/2026 View at CMS
1011684327 AstraZeneca Pharmaceuticals LP $1,665.00 08/11/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1015151977 AstraZeneca Pharmaceuticals LP $15.34 02/04/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1023301879 Eisai Inc. $24.97 01/12/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1023301881 Eisai Inc. $20.13 03/01/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1025939991 Gilead Sciences, Inc. $16.69 10/19/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1040021059 Stemline Therapeutics Inc. $1,080.00 02/08/2023 Consulting Fee Undisputed 01/23/2026 View at CMS
1056927917 Tolmar, Inc. $21.17 12/19/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
1058783317 Foundation Medicine, Inc. $39.63 10/17/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
991989803 Novartis Pharmaceuticals Corporation $3.88 05/26/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
991989807 Novartis Pharmaceuticals Corporation $21.90 06/15/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
991989811 Novartis Pharmaceuticals Corporation $14.67 10/11/2023 Food and Beverage Undisputed 01/23/2026 View at CMS
993424309 NOVARTIS PHARMACEUTICALS CORPORATION $83.33 01/14/2023 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
993424311 NOVARTIS PHARMACEUTICALS CORPORATION $83.33 02/15/2023 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.